SHANGHAI, China, July 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that Dr. Richard M. Soll has joined WuXi PharmaTech as Vice President of Medicinal Chemistry.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
As a pharmaceutical veteran, Dr. Soll brings over 25 years of scientific experience and proven leadership capability to his new role in WuXi. Prior to joining WuXi, Dr. Soll worked at TargeGen Inc., a San Diego based biotechnology company, as Vice President of Research and Development and Chief Scientific Officer from March 2003 to March 2008. Before joining TargeGen, Dr. Soll held senior positions with increasing responsibilities at Ontogen Corporation and 3-Dimensional Pharmaceutical, Inc.
Dr. Soll is well recognized and respected for his scientific acuity from the academic and industry circles. Amongst his most recent achievements are first-in-class drug development nomination candidates and clinical development drugs for potential treatment for cancer, thrombosis, ocular disease, inflammation, edema and myeloproliferative disorders.
As the Vice President of Medicinal Chemistry Dr. Soll will help the company to expand and strengthen its medicinal chemistry services platform. Dr. Soll will report directly to Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.
"I am very excited to welcome Dr. Soll on board to lead and expand our
already strong medicinal chemistry unit," commented Dr. Ge Li, Chairman and
Chief Executive Officer of WuXi PharmaTech. "Previously a customer of WuXi,
Rich has a unique perspective on how to maximize service value creation for
clients. His broad experience in the pharmaceutical industry and proven
track record
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2008 PR Newswire. All rights reserved |